Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 14Lung Neoplasms 11Breast Neoplasms 9Colorectal Neoplasms 8Prostatic Neoplasms 7Stomach Neoplasms 3Rectal Neoplasms 3Polycystic Ovary Syndrome 3Neoplasm Metastasis 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Smoking Cessation 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic cancer, adult 2Ovarian Neoplasms 2Neoplastic Cells, Circulating 2Motor Activity 2Lymphoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia 2Endometrial Neoplasms 2Disease 2Wilms Tumor 1Venous Thromboembolism 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer 1Testicular Germ Cell Tumor 1

Interventions

Carboplatin 71Paclitaxel 49Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 39Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8capmatinib 7Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6Mastectomy, Segmental 6ceritinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Hematologic Tests × Clear all
NCT02839681 2019-05-21

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 12 charts
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡